Shots:
- Sanofi has licensed an undisclosed Nurix program targeting a previously undruggable transcription factor for autoimmune diseases under their Dec 2019 deal
- As per the deal, Nurix used its DEL-AI platform to develop E3 ligase-targeting degraders, with Sanofi having rights to license them. Nurix can co-develop & co-promote up to 2 US products, sharing US profits & losses 50/50 & earning ex-US royalties, while non-optioned programs yield milestones & global royalties
- Nurix received a total of $105M till date under this alliance, incl. $55M upfront, $15M license extension fee, & $22M for expansion, plus is eligible to get ~$465M in development, regulatory, & commercial milestones/licensed program as well as royalties on future sales
Ref: Nurix Therapeutics | Image: Sanofi & Nurix Therapeutics
Related News:- Alnylam Pharmaceuticals and Sanofi Report the US FDA’s Approval of Qfitlia (Fitusiran) to Treat Hemophilia A or B
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
